Pyxis Oncology, Inc.
NASDAQ:PYXSBiotechnology
Healthcare
$1.41 +5.53%
+$0.11 today
- Market cap
- $168.65M
- Beta
- 1.43
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$1.29
52W Low $0.97High $5.55
Volume 0.75M
Average 0.50M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$63.50M
FY 2025 · Annual
Investing Cash Flow
$58.86M
FY 2025 · Annual
+621.7% YoYFinancing Cash Flow
$594,000.00
FY 2025 · Annual
-99.0% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (75.98M) | (120.72M) | (73.79M) | (77.33M) | (79.62M) |
| Depreciation & Amortization | 647K | 709K | 1.93M | 2.98M | 4.51M |
| Deferred Income Tax | 6.28M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.44M | 15.76M | 16.95M | 12.95M | 11.8M |
| Change in Working Capital | 6.68M | 4.5M | (11.66M) | (11.82M) | 1.94M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 4.64M | (8.33M) | (3.51M) | 1.2M | 6.03M |
| Other Working Capital | 2.03M | 12.83M | (8.16M) | (13.02M) | (4.08M) |
| Other Non-Cash Items | 20.6M | 10.41M | (4.13M) | 15.56M | (2.14M) |
| Operating Cash Flow | (35.33M) | (89.34M) | (70.71M) | (57.67M) | (63.5M) |
| Capital Expenditures | (540K) | (6.4M) | (6.73M) | (237K) | (9K) |
| Acquisitions (Net) | (50K) | 0 | 6.66M | 0 | 0 |
| Purchases of Investments | (50K) | 0 | (196.83M) | (160.12M) | (107.01M) |
| Sales of Investments | 50.05K | 0 | 92.05M | 168.51M | 165.87M |
| Other Investing Activities | (50) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (590K) | (6.4M) | (104.85M) | 8.16M | 58.86M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 152.3M | 0 | 6.12M | 59.05M | 742K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 167K | 183K | (193K) | 280K | (148K) |
| Financing Cash Flow | 304.04M | 183K | 5.93M | 59.33M | 594K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 268.13M | (95.55M) | (169.63M) | 9.81M | (4.05M) |
| Free Cash Flow | (35.87M) | (95.73M) | (77.44M) | (57.91M) | (63.51M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$79.6M
+ D&A$4.5M
+ Stock-Based Comp$11.8M
+ Deferred Tax$0
+ Working Capital$1.9M
- Other Non-Cash-$2.1M
= Operating Cash Flow-$63.5M
- Capex-$9.0K
= Free Cash Flow-$63.5M
Analysis
FY2025 free cash flow is -$63.5M. FCF conversion is 79.8% of net income. Operating cash flow was -$63.5M, with capex of -$9.0K. The largest bridge item is Stock-Based Comp at $11.8M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 6, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 3, 2026 |
Does PYXS generate free cash flow?
Pyxis Oncology, Inc. (PYXS) generated -$63.51M of free cash flow in fiscal 2025.
How much operating cash flow does PYXS produce?
Operating cash flow was -$63.50M, before capital expenditures of $9,000.00.
Continue the stock analysis
Jump to another research area for this company.